Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.

We surveyed 306 former injection drug users receiving methadone maintenance treatment in 1997-1998 in Providence, RI regarding, (1) knowledge of hepatitis C transmission; (2) the concordance of self-knowledge of hepatitis C virus (HCV) status versus actual status; (3) perceived risk of cirrhosis; and (4) willingness to receive therapy for hepatitis C. The seroprevalence of HCV was 87%. While 77% of participants knew that HCV could be sexually transmitted, 30% did not know that condoms are protective against transmission. Thirty of 45 persons who reported they were HCV seronegative were actually seropositive; 51 of 62 persons (82%) who reported they had never been HCV tested or did not know their HCV status were serologically HCV-positive. Over half of respondents (53%) would "definitely" or "probably" use interferon therapy for viral hepatitis when informed of the risks and benefits of treatment. We found significant gaps in knowledge about HCV among IDUs. Serologic confirmation of HCV status is important among drug users, as self-report of HCV infection is often unreliable. This population, with its high prevalence of HCV, may be interested in treatments that include interferon.

Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use.

Methadone maintenance patients infected with human immunodeficiency virus (HIV) currently receiving antiretroviral therapy had HIV RNA testing and were surveyed regarding their adherence to their treatment regimens. Adherence was measured using self-report on four questions relating to medication use in the last day and last month and whether the patient took "drug holidays." Of the patients (N = 42), 52% were receiving two-drug antiretroviral therapy and 48% were receiving triple therapy that included a protease inhibitor. Persons on triple therapy reported higher rates of adherence on all measures and were more likely to have undetectable HIV RNA levels than persons on dual therapy (60% vs. 50%). Ongoing illicit drug injection was the only factor significantly associated (p < .05) with multiple measure nonadherence; however, it was not associated with undetectable HIV RNA level. Levels of nonadherence were comparable to estimates from other chronic diseases, but this finding has important implications for patients receiving highly active antiretroviral therapy.

Depression among needle exchange program and methadone maintenance clients.

The objective of this study was to compare the prevalence of major depression in two cohorts of injection drug users, those enrolled in a Rhode Island Methadone Maintenance Treatment Program (MMTP) and those enrolled in a Rhode Island Needle Exchange Program (NEP) using cross-sectional interviews. Symptomatic and duration criteria for major depression in the last 6 months were identified using the Structured Clinical Interview for DSM-III-R (SCID). Among 528 persons interviewed, 54% of those in NEP and 42% of those in MMTP met criteria for major depression. Using multivariate logistic regression, women (odds ratio [OR] 2.5; 95% confidence interval [CI] 1.7-3.7), persons with alcohol use disorders (OR 1.7; 95% CI 1.1-2. 7), and persons without a current partner (OR 1.8; 95% CI 1.2-2.6) were more likely to be depressed controlling for age, race, education and HIV status. Persons enrolled in MMTP were less likely to be depressed (OR 0.6; 95% CI 0.4-0.8) than NEP. Higher rates of depression were found among NEP attendees than among those enrolled in MMTP. Mental health referrals should be part of the growing number of needle exchanges in the United States.

Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance.

HIV-infected persons receiving methadone maintenance must often seek their medical care at a separate site. However, little data is available on the receipt of antiretroviral therapy (ART), beliefs about ART, and influences on the decision to initiate ART among those referred off-site. HIV-infected injection drug users (n = 72) were interviewed at three methadone maintenance programs; 83% with CD4 cell counts under 500 reported that they had received ART. Of these persons, 56% had used three drug combination therapy. Beliefs about the benefits of ART included: increased survival, 96%; decreased viral load 87%; decreased HIV-related infections 87%; could cure HIV, 29%. For those receiving ART, physician input, CD4 count, and possible side effects were more important than friends, family or mass media in deciding to start ART. We conclude that the model of referral for HIV care off-site does not appear to impede access to ART for HIV-infected IDUs in methadone maintenance.